Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Gene Therapy Bioassays Market Size Forecast: How Big Could The Market Get By 2030?
The gene therapy bioassays market has shown substantial growth in recent years. It is forecast to increase from $1.21 billion in 2025 to $1.41 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.5%. This market’s past expansion is linked to factors such as the rise in gene therapy research programs, the broadening of viral vector manufacturing, increased clinical trial engagement, the implementation of standardized bioassay protocols, and enhanced regulatory oversight concerning gene therapy products.
The gene therapy bioassays market size is set for substantial growth over the next few years, with projections indicating it will reach $2.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 16.7%.
This growth during the forecast period is propelled by several factors, including the increasing commercialization of gene therapies, a rising demand for high-throughput bioassay solutions, the expansion of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, and an increasing focus on assay automation and reproducibility.
Major developments expected in the forecast period encompass the increasing adoption of cell-based potency assays, a rising demand for viral vector characterization tests, the growing use of automated bioassay platforms, an expansion of regulatory-compliant assay validation, and an enhanced focus on functional gene expression analysis.
Get A Free Sample Report With In-Depth Market Insights:
Gene Therapy Bioassays Market Growth Factors: What’s Supporting Expansion?
The rising volume of gene therapy clinical trials is anticipated to stimulate growth within the gene therapy bioassays market. These trials rigorously assess the safety, effectiveness, and biological performance of gene-based treatments administered to human subjects. The growth of these trials is fueled by augmented research and development endeavors and increasing financial backing from biopharmaceutical entities striving to meet unmet medical needs via pioneering genetic therapies. Gene therapy bioassays play a crucial role in clinical development by supplying essential analytical evaluations to determine biological activity, potency, safety, and mechanism of action at every development stage; regulatory stipulations become progressively stringent as programs advance through clinical phases. For example, in January 2026, the Bioindustry Association (BIA), a national trade association based in the UK, reported that the UK had 193 ongoing advanced therapy clinical trials, with over 80% specifically targeting gene therapies. Consequently, the escalation in gene therapy clinical trials is acting as a primary driver for the expansion of the gene therapy bioassays market.
Gene Therapy Bioassays Market Segment Landscape And Growth Outlook
The gene therapy bioassays market covered in this report is segmented –
1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types
2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services
3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications
4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories
Subsegments:
1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays
2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays
3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays
4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays
Gene Therapy Bioassays Market Industry Trends: What’s Reshaping Demand?
Major companies operating in the gene therapy bioassays market are prioritizing the integration of artificial intelligence and machine learning into bioassay analysis, specifically through AI-enabled digital PCR data interpretation. This focus aims to improve accuracy, diminish experimental variability, hasten result turnaround, and refine the evaluation of therapeutic efficacy and safety during gene therapy development. AI-enabled dPCR data interpretation leverages advanced algorithms to automate result analysis, differentiate true signals from background noise, and precisely quantify viral genomes or vector copy number with minimal human involvement. For instance, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, introduced expanded QIAcuity lentivirus solutions, which include the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions incorporate algorithm-driven absolute quantification, offer multiplex and singleplex assay compatibility for vector genome and vector copy number analysis, and provide software-assisted data analysis workflows designed to facilitate regulatory-compliant decision-making in gene therapy bioassay applications.
Gene Therapy Bioassays Market Key Participants And Competitive Landscape
Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories
View The Full Gene Therapy Bioassays Market Report:
Gene Therapy Bioassays Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy bioassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model